IP Library Granted Patent US 7,846,465
Granted Patent B1
US 7,846,465 · App. 09/980,150 · Granted Dec 7, 2010

Method of using autologous fibroblasts to promote healing of wounds and fistulas

Assignee: Fibrocell Science, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,846,465
App. No.
09/980,150
Granted
Dec 7, 2010
Kind
B1
Abstract

The invention provides a method or promoting healing of a wound, e.g., an epithelial wound, in an animal. The method involves administering cultured autologous fibroblasts to the wound.

Claims (18)

1. A method of promoting wound healing in an animal, wherein said wound is susceptible to healing upon administration of autologous fibroblasts, which method comprises:

(a) obtaining autologous fibroblasts

(b) culturing the fibroblasts in a culture medium such that the cultured fibroblasts are non-immunogenic when administered, and

(c) administering the autologous fibroblasts in the form of an injection to a wound in said animal, wherein said fibroblasts promote healing of the wound.

2. The method of claim 1 , wherein said animal is a human.

3. The method of claim 2 , wherein said autologous fibroblasts are derived from a tissue which is the same type of tissue as a tissue of which the wound is comprised.

4. The method of claim 2 , wherein said fibroblasts are cultured in the animal's own serum.

5. The method of claim 2 , wherein said fibroblasts are passaged in culture less than about ten times.

6. The method of claim 5 , wherein said fibroblasts are passaged in culture from about four to about six times.

7. The method of claim 2 , wherein about 20 million fibroblasts are administered per administration.

8. The method of claim 2 , wherein said wound is a chronic non-healing wound.

9. The method of claim 2 , wherein said wound is an epithelial wound.

10. The method of claim 9 , wherein said wound is due to venous stasis.

11. The method of claim 2 , wherein said wound is a mucosal wound.

12. The method of claim 11 , wherein said wound is due to a gastric ulcer.

13. The method of claim 12 , wherein said autologous fibroblasts are administered by endoscopic injection.

14. The method of claim 11 , wherein said wound is due to a duodenal ulcer.

15. The method of claim 11 , wherein said wound is an anal fissure.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL TECHNOLOGIES, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 055641/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL SCIENCE, INC.
To: CASTLE CREEK BIOSCIENCES, LLC
Reel/Frame 055642/0372 →
CHANGE OF NAME Recorded Oct 3, 2011
From: ISOLOGEN TECHNOLOGIES, INC.
To: FIBROCELL TECHNOLOGIES, INC.
Reel/Frame 027008/0939 →
CHANGE OF NAME Recorded Jul 15, 2011
From: ISOLAGEN, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 026601/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2003
From: REVAZOVA, ELENA
To: KELLER, GREGORY S.
Reel/Frame 014088/0052 →